Franco-Nevada Corp. (0QYZ)
London Exchange · UK · prices in CAD · close of 21 Oct 2026
Key indicators
| Last close | CAD 340.03 |
|---|---|
| 52-week range | 209.48 – 385.70 |
| Return, 1 month / 3 months | −7.7% / +21.1% |
| Return, 1 year / 3 years | +42.9% / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 44 |
| Volatility (1 year) | 43.2% |
| Worst drawdown (1 year) | -27.3% |
| Average daily value traded | 0.45M CAD |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Franco-Nevada Corp. is a royalty and streaming company focused on gold and other precious metals. It provides upfront financing to mining operators and in return receives a portion of the revenue or metal produced from their mines, without operating the mines itself. Its portfolio spans gold, silver, platinum group metals and energy assets, with interests in mines across several countries. The company is based in Toronto, Canada, and serves investors seeking exposure to mining through royalty and streaming agreements.
On this site Franco-Nevada Corp. appears as a stock on the London Exchange (UK), code 0QYZ, with prices in Canadian dollars (CAD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Franco-Nevada Corp. (0QYZ) trades on the London Exchange in UK. It last closed at CAD 340.03 on 21 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 1,625 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.9% and over the last three months it rose 21.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 65 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.2% | ||
| From 52-week high | -10.8% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 21.1% | ||
| 6-month return | -3.2% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 43.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.3% | ||
| Liquidity | 45 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.45M CAD | ||
| Zero-volume days | 3.3% | ||
| Income | 64 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +1.6% |
|---|---|
| 1 month | −7.7% |
| 3 months | +21.1% |
| 6 months | −3.2% |
| 1 year | +42.9% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 352.73 / 329.41 |
|---|---|
| Golden / death cross (60 days) | Golden, 31 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.80 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Sep 2026 | CAD 0.6081 |
| 11 Jun 2026 | CAD 0.6168 |
| 12 Mar 2026 | CAD 0.5993 |
| 4 Dec 2025 | CAD 0.5295 |
| 11 Sep 2025 | CAD 0.5260 |
| 12 Jun 2025 | CAD 0.5172 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.